KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Operating Expenses: 2013-2024

Historic Operating Expenses for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to $4.4 million.

  • Palvella Therapeutics' Operating Expenses rose 107.95% to $4.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $14.1 million, marking a year-over-year increase of 18.75%. This contributed to the annual value of $14.1 million for FY2024, which is 18.75% up from last year.
  • Latest data reveals that Palvella Therapeutics reported Operating Expenses of $4.4 million as of Q4 2024, which was down 13.75% from $5.1 million recorded in Q3 2024.
  • Over the past 5 years, Palvella Therapeutics' Operating Expenses peaked at $31.3 million during Q3 2023, and registered a low of -$54.9 million during Q4 2023.
  • Its 3-year average for Operating Expenses is $7.9 million, with a median of $16.7 million in 2022.
  • Its Operating Expenses has fluctuated over the past 5 years, first slumped by 416.14% in 2023, then surged by 107.95% in 2024.
  • Palvella Therapeutics' Operating Expenses (Quarterly) stood at $14.3 million in 2020, then soared by 36.07% to $19.4 million in 2021, then decreased by 10.68% to $17.4 million in 2022, then plummeted by 416.14% to -$54.9 million in 2023, then surged by 107.95% to $4.4 million in 2024.
  • Its last three reported values are $4.4 million in Q4 2024, $5.1 million for Q3 2024, and $2.9 million during Q2 2024.